News All of Ferrer’s information, just a click away Home News normal Apply Ferrer, strategic partner of Barcelona+B, the initiative to promote a more prosperous, sustainable and inclusive city . Wed, 04/27/2022 - 09:05 More than 400 employees from Ferrer take part in a social initiative in Spain . Fri, 04/08/2022 - 10:34 Ferrer, the first pharmaceutical company committed to recovering waste medicines in Costa Rica . Wed, 03/23/2022 - 17:51 Details of Clinical Trial ADORE for Amyotrophic Lateral Sclerosis (ALS) . Thu, 02/24/2022 - 09:17 Ferrer announces distribution agreement with United Therapeutics for treprostinil inhalation solution for pulmonary hypertension associated with interstitial lung disease . Wed, 02/23/2022 - 15:24 Ferrer becomes a B Corp for its positive impact in society . Tue, 01/25/2022 - 15:06 Ferrer joins Barcelona + B, a project to bring the business community closer to the SDGs . Mon, 11/29/2021 - 17:47 First patient enrolled in Ferrer's FNP122 ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS) treatment . Mon, 11/08/2021 - 14:12 World Stroke Day - "Another one?" campaign . Fri, 10/29/2021 - 06:53 Ferrer signs license agreement to develop an oral formulation treatment for patients with ALS . Wed, 10/20/2021 - 09:29 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
Ferrer, strategic partner of Barcelona+B, the initiative to promote a more prosperous, sustainable and inclusive city . Wed, 04/27/2022 - 09:05
More than 400 employees from Ferrer take part in a social initiative in Spain . Fri, 04/08/2022 - 10:34
Ferrer, the first pharmaceutical company committed to recovering waste medicines in Costa Rica . Wed, 03/23/2022 - 17:51
Ferrer announces distribution agreement with United Therapeutics for treprostinil inhalation solution for pulmonary hypertension associated with interstitial lung disease . Wed, 02/23/2022 - 15:24
Ferrer joins Barcelona + B, a project to bring the business community closer to the SDGs . Mon, 11/29/2021 - 17:47
First patient enrolled in Ferrer's FNP122 ADORE Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS) treatment . Mon, 11/08/2021 - 14:12
Ferrer signs license agreement to develop an oral formulation treatment for patients with ALS . Wed, 10/20/2021 - 09:29